SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

NCT Number	NCT06743126
Lead Sponsor	Immatics US, Inc.
Conditions	Melanoma, Cutaneous Malignant
Enrollment	360 participants
Start Date	2025-01-14
Primary Completion	2028-01 (estimated)
Study Completion	2031-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-10